ArticleCurrent oncology (Toronto, Ont.)2009
Role of cytokine therapy for renal cell carcinoma in the era of targeted agents.
Article in Current oncology (Toronto, Ont.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- IFI44 Promotes Clear Cell Renal Cell Carcinoma Progression via PRDX1 and Predicts Poor Prognosis.Research (Washington, D.C.) · 2026Article
- Microtubule dynamics is a therapeutic vulnerability in VHL-deficient renal cell carcinoma.International journal of biological sciences · 2025Article
- The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma.Cancers · 2024Review
- Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast.Oncology and therapy · 2024Article
- Cytoreductive Nephrectomy Following Immunotherapy: Evolution, Pearls, and Pitfalls of Treatment.Journal of cellular immunology · 2024Article
- Recent Advances in Single-Cell RNA-Sequencing of Primary and Metastatic Clear Cell Renal Cell Carcinoma.Cancers · 2023Review
- Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.Cancer cell · 2023Article
- Review
- Novel Expression of Thymine Dimers in Renal Cell Carcinoma, Demonstrated through Immunohistochemistry.Biomedicines · 2022Article
- Antibody-Drug Conjugates in Uro-Oncology.Targeted oncology · 2022Review
- Harnessing cytokines and chemokines for cancer therapy.Nature reviews. Clinical oncology · 2022Review
- Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma.Frontiers in medicine · 2022Review
- Poly(ADP)-Ribosylation Inhibition: A Promising Approach for Clear Cell Renal Cell Carcinoma Therapy.Cancers · 2021Article
- Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma.World journal of urology · 2021Review
- Mapping the immune environment in clear cell renal carcinoma by single-cell genomics.Communications biology · 2021Article
- Nodal is involved in chemoresistance of renal cell carcinoma cells via regulation of ABCB1.Journal of Cancer · 2021Article
- Imaging for Metastatic Renal Cell Carcinoma.The Urologic clinics of North America · 2020Review
- Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.Molecular cancer therapeutics · 2019Article
- Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy.Frontiers in oncology · 2019Review
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Starting in the late 1980s, cytokines were considered the mainstay of treatment for locally advanced or metastatic renal cell carcinoma (rcc) because of a lack of improved survival with either chemotherapy or hormonal therapy alone. The cytokine agents interferon alfa (IFNalpha) and interleukin-2 (IL-2) have been the most evaluated, but a low overall response rate and a marginal survival advantage, coupled with significant toxicity, make these therapies less than ideal. Although complete tumour responses have occasionally been seen with high-dose il-2, this therapy is associated with significant morbidity and mortality, and its approval has been based on limited nonrandomized evidence. Newer anti-angiogenesis agents have been evaluated as single agents and in combination with INFalpha, and these are now considered the standard of care for most patients with rcc. However, cytokines may still occasionally be recommended when angiogenesis inhibitors are not available or are contraindicated. In the present paper, we discuss the evidence for the use of cytokine therapy in the setting of pre- and post-targeted therapy for RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.